ArticleCancers2022

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies.

Aleksandra Urban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.